Holen Sie sich die Stockscreener-App
0.4007
0.65%
0.0026
Handel nachbörslich:
.41
0.0093
+2.32%
Athira Pharma Inc Aktie (ATHA) Neueste Nachrichten
Exit strategy if you’re trapped in Athira Pharma Inc.Insider Buying & Low Risk Entry Point Guides - Newser
Can machine learning forecast Athira Pharma Inc. recovery2025 Analyst Calls & Fast Moving Market Watchlists - Newser
Will Athira Pharma Inc. face regulatory challenges2025 Momentum Check & Reliable Breakout Stock Forecasts - sundaytimes.kr
Traders Consider Averaging Down in Athira Pharma Inc.2025 AllTime Highs & Weekly Hot Stock Watchlists - sundaytimes.kr
Will Athira Pharma Inc. rebound enough to break even2025 Technical Patterns & Fast Entry High Yield Tips - Newser
Athira Pharma presents results from Phase 1 trial of ATH-1105 at ALS Nexus - MSN
How to monitor Athira Pharma Inc. with trend dashboardsPortfolio Gains Summary & Technical Confirmation Trade Alerts - Newser
Athira Pharma Inc. Tests 50 Day MA After Sharp DeclineJuly 2025 Setups & High Accuracy Trade Signal Alerts - metrotimes.co.kr
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 - GlobeNewswire
Athira Pharma reports positive Phase 1 results for ALS drug candidate - Investing.com
Athira Pharma Inc. stock prediction for this weekJuly 2025 EndofMonth & Reliable Volume Spike Alerts - Newser
Novel Oral ALS Drug Candidate ATH-1105 Demonstrates Favorable Safety Profile in Early Trial - Stock Titan
Are Bears Losing Grip on Athira Pharma Inc.Portfolio Value Summary & Verified Chart Pattern Trade Signals - classian.co.kr
Athira Pharma Reports Reduced Losses Amid Financial Challenges - MSN
Athira Pharma Inc. Testing Reversal Zone on Weekly ChartRecession Risk & Accurate Technical Buy Alerts - 선데이타임즈
Sentiment analysis tools applied to Athira Pharma Inc.July 2025 PreEarnings & Growth Focused Entry Point Reports - Newser
Analyzing Athira Pharma Inc. with risk reward ratio charts2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - Newser
What moving averages say about Athira Pharma Inc.Market Growth Summary & AI Driven Stock Movement Reports - Newser
Athira Pharma’s SWOT analysis: ALS drug developer’s stock faces pivotal moment - Investing.com
Is Athira Pharma Inc. building a consolidation baseReal-Time Entry Signals for Top Stocks - Newser
Competitive Positioning of Athira Pharma Inc.: Is It Leading or LaggingPredictive Screener for Daily Trade Watch - Newser
Reversal indicators forming on Athira Pharma Inc. stockFree Consistent Profit Pattern Recognition Tools - Newser
Can momentum traders help lift Athira Pharma Inc.Free Risk-Adjusted Picks With Exit Strategy - Newser
Using R and stats models for Athira Pharma Inc. forecastingFree Weekly Chart Analysis With Entry Advice - Newser
What to do if you’re stuck in Athira Pharma Inc.Free Stock Selection With High Accuracy - Newser
Using fundamentals and technicals on Athira Pharma Inc.Low Risk Strategy with Smart Entry Zones - Newser
Why Athira Pharma Inc. stock attracts strong analyst attentionFast-Growing Stock Candidates - sisain.net
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Athira (ATHA) Q2 Loss Narrows 74% - The Motley Fool
Athira (ATHA) Q2 Loss Narrows 74% - The Globe and Mail
Athira Pharma Q2 net loss narrows - MarketScreener
Athira's New ALS Drug ATH-1105 Achieves Critical Safety Milestone in Phase 1 Trial, Strategic Review Continues - Stock Titan
Can technical indicators confirm Athira Pharma Inc.’s reversalWeekly Stock Market Strategy Summary - Newser
Athira Pharma (ATHA) to Release Earnings on Thursday - Defense World
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):